Rodman & Renshaw initiated coverage of Sana Biotechnology (SANA) with a Buy rating and $16 price target The firm, which says its target reflects “the transformative clinical validation” of the company’s hypoimmune platform in Type 1 Diabetes and the emerging in vivo CAR T franchise, sees shares trading at “a compelling entry point” at the early stages of these platforms.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- SANA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Sana Biotechnology options imply 5.3% move in share price post-earnings
- Sana Biotechnology Rebalances Board Classes With Director Shift
- Sana Biotechnology price target raised to $7 from $6 at Wedbush
- Sana Biotechnology: Mayo Clinic Collaboration and UP421 Data De‑Risk SC451 and Support Buy Rating on Type 1 Diabetes Momentum